Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.
about
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyCan we prevent antimicrobial resistance by using antimicrobials better?Cancer in light of experimental evolutionPharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica.In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?What in vitro models of infection can and cannot do.Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery.Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.Optimizing drug exposure to minimize selection of antibiotic resistance.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusionsModeling the mechanism of postantibiotic effect and determining implications for dosing regimens.Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa
P2860
Q24519008-4096C484-A318-4184-9F06-476060588E8FQ26829707-47920969-0273-480A-9756-B04B1295F068Q28727500-F31DC853-80B9-43D6-8B5D-658A665727F6Q33761118-7A74F115-3C1D-49CB-B0E1-F25DDD495A99Q33982098-2475F2CA-8CAD-4522-A6FF-8BFEACCD7FDAQ34112823-EBFA7D8D-E6C3-4B62-A531-03DE52E14BB3Q34347908-EF349C54-2EFA-45DC-8C03-3A8FFEB987B8Q34443398-8F2474A7-7156-49CB-AAFA-EF75E5075A4EQ34527809-FDFF90CE-BAF5-4A0E-ABC4-F6F1D23F3658Q35685485-3C27E9D4-FB38-4B22-8165-A27A41E17903Q36903693-4D261EEB-151F-47AC-A3B7-B71BB560FCAFQ37568933-D7DC6264-60FA-4597-BF57-146280B32534Q37624733-2569944A-0684-4F82-8431-0BA23DED2BCDQ38692072-67ECF292-F1A1-44C4-80D2-3352D5126E32Q39731788-10479C1E-25EC-4426-AE11-DD0D7151D7D0Q39746394-E67F0B37-7D44-4308-8BCC-2D21D6690325Q39783646-4CB3314B-1C8A-4C5D-ADC4-083FA425759AQ40005632-F60CEA26-0953-4D74-8DB6-2591C91085E1Q40285699-17898210-E69F-48E9-B71C-E4E27C1420B1Q40621865-D4A3520A-977A-47FB-A6CB-D07C177C1786Q40666822-6DF44220-7B5A-4FE2-B241-36419882838BQ57240410-DDF3C897-04E6-4553-B736-87CE52C4DB7F
P2860
Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Dose ranging and fractionation ...... n in vitro model of infection.
@ast
Dose ranging and fractionation ...... n in vitro model of infection.
@en
type
label
Dose ranging and fractionation ...... n in vitro model of infection.
@ast
Dose ranging and fractionation ...... n in vitro model of infection.
@en
prefLabel
Dose ranging and fractionation ...... n in vitro model of infection.
@ast
Dose ranging and fractionation ...... n in vitro model of infection.
@en
P2093
P2860
P356
P1476
Dose ranging and fractionation ...... n in vitro model of infection.
@en
P2093
Gilbert DH
Marchbanks CR
Robillard NJ
P2860
P304
P356
10.1128/AAC.37.9.1756
P407
P577
1993-09-01T00:00:00Z